Moderna Net Worth
Moderna Net Worth Breakdown | MRNA |
Moderna Net Worth Analysis
Moderna's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Moderna's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Moderna's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Moderna's net worth analysis. One common approach is to calculate Moderna's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Moderna's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Moderna's net worth. This approach calculates the present value of Moderna's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Moderna's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Moderna's net worth. This involves comparing Moderna's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Moderna's net worth relative to its peers.
Enterprise Value |
|
To determine if Moderna is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Moderna's net worth research are outlined below:
| Moderna generated a negative expected return over the last 90 days | |
| Moderna has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 3.24 B. Net Loss for the year was (3.56 B) with loss before overhead, payroll, taxes, and interest of (2.77 B). | |
| Moderna currently holds about 8.35 B in cash with (3 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.73. | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from channelnewsasia.com: White House withdraws vaccine critic Weldon for CDC director |
Moderna uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Moderna. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Moderna's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Moderna's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Moderna is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Moderna backward and forwards among themselves. Moderna's institutional investor refers to the entity that pools money to purchase Moderna's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Norges Bank | 2024-12-31 | 3.9 M | Wellington Management Company Llp | 2024-12-31 | 3.9 M | Jane Street Group Llc | 2024-12-31 | 3.6 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 3.6 M | Manufacturers Life Insurance Co | 2024-12-31 | 3.3 M | Goldman Sachs Group Inc | 2024-12-31 | 3.3 M | Banque Pictet & Cie Sa | 2024-12-31 | 3.1 M | Northern Trust Corp | 2024-12-31 | 3 M | Voloridge Investment Management, Llc | 2024-12-31 | 2.6 M | Vanguard Group Inc | 2024-12-31 | 40.3 M | Baillie Gifford & Co Limited. | 2024-12-31 | 38.9 M |
Follow Moderna's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.38 B.Market Cap |
|
Project Moderna's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.24) | |
| Return On Capital Employed | (0.33) | (0.31) | |
| Return On Assets | (0.25) | (0.24) | |
| Return On Equity | (0.33) | (0.31) |
When accessing Moderna's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Moderna's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Moderna's profitability and make more informed investment decisions.
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Moderna's management manipulating its earnings.
Evaluate Moderna's management efficiency
Moderna has return on total asset (ROA) of (0.1514) % which means that it has lost $0.1514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2877) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.24. The current year's Return On Capital Employed is expected to grow to -0.31. At present, Moderna's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 6 B, whereas Total Assets are forecasted to decline to about 9.6 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 28.39 | 16.12 | |
| Tangible Book Value Per Share | 28.15 | 16.07 | |
| Enterprise Value Over EBITDA | (4.35) | (4.56) | |
| Price Book Value Ratio | 1.46 | 1.39 | |
| Enterprise Value Multiple | (4.35) | (4.56) | |
| Price Fair Value | 1.46 | 1.39 | |
| Enterprise Value | 33.5 B | 35.2 B |
Leadership effectiveness at Moderna is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 2.2216 | Revenue | Quarterly Revenue Growth (0.66) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moderna insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephane Bancel over two weeks ago Acquisition by Stephane Bancel of 357065 shares of Moderna at 30.96 subject to Rule 16b-3 | ||
Hoge Stephen over a month ago Acquisition by Hoge Stephen of 523 shares of Moderna subject to Rule 16b-3 | ||
James Mock over two months ago Disposition of 1453 shares by James Mock of Moderna subject to Rule 16b-3 | ||
Noubar Afeyan over six months ago Disposition of 2100 shares by Noubar Afeyan of Moderna at 121.5699 subject to Rule 16b-3 | ||
Noubar Afeyan over six months ago Disposition of 7996 shares by Noubar Afeyan of Moderna at 122.0689 subject to Rule 16b-3 | ||
James Mock over six months ago Disposition of 705 shares by James Mock of Moderna at 101.9281 subject to Rule 16b-3 |
Moderna Corporate Filings
| 11th of March 2025 Other Reports | ViewVerify | |
F4 | 10th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 21st of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 14th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Moderna Earnings per Share Projection vs Actual
Moderna Corporate Management
| Shannon Klinger | Chief Secretary | Profile | |
| Brad Miller | Chief Officer | Profile | |
| Melanie MBA | Chief Officer | Profile | |
| James Mock | Chief Officer | Profile | |
| Stephane Bancel | CEO Director | Profile | |
| John Reynders | Chief Officer | Profile | |
| Ruchi Jain | Principal Scientist | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (9.28) | Revenue Per Share | Quarterly Revenue Growth (0.66) | Return On Assets |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.